# Valina L Dawson

## List of Publications by Year in Descending Order

**Source:** https://exaly.com/author-pdf/3791571/valina-l-dawson-publications-by-year.pdf
**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|---|---|---|---|
| 367 papers | 60,569 citations | 121 h-index | 243 g-index |
| 412 ext. papers | 68,465 ext. citations | 11.2 avg, IF | 7.47 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 367 | Intracellular Signaling: Mediators and Protective Responses **2022**, 74-81.e5 | | |
| 366 | Interleukin-6 triggers toxic neuronal iron sequestration in response to pathological α-synuclein.. *Cell Reports*, **2022**, 38, 110358 | 10.6 | 0 |
| 365 | Deubiquitinase CYLD acts as a negative regulator of dopamine neuron survival in Parkinson's disease.. *Science Advances*, **2022**, 8, eabh1824 | 14.3 | 0 |
| 364 | STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2118819119 | 11.5 | 5 |
| 363 | A high-affinity cocaine binding site associated with the brain acid soluble protein 1.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2200545119 | 11.5 | 0 |
| 362 | Waiting for PARIS-A Biological Target in Search of a Drug. *Journal of Parkinson's Disease*, **2021**, | 5.3 | 1 |
| 361 | Integrative genome-wide analysis of dopaminergic neuron-specific PARIS expression in Drosophila dissects recognition of multiple PPAR-γ-associated gene regulation. *Scientific Reports*, **2021**, 11, 21500 | 4.9 | 1 |
| 360 | Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. *Pharmacological Reviews*, **2021**, 73, 33-97 | 22.5 | 2 |
| 359 | TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease. *Neuron*, **2021**, 109, 3758-3774.e11 | 13.9 | 1 |
| 358 | Lymphocyte Activation Gene 3 (Lag3) Contributes to α-Synucleinopathy in α-Synuclein Transgenic Mice. *Frontiers in Cellular Neuroscience*, **2021**, 15, 656426 | 6.1 | 8 |
| 357 | The cell biology of Parkinson's disease. *Journal of Cell Biology*, **2021**, 220, | 7.3 | 15 |
| 356 | AIF3 splicing switch triggers neurodegeneration. *Molecular Neurodegeneration*, **2021**, 16, 25 | 19 | 0 |
| 355 | Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer's disease. *Acta Neuropathologica Communications*, **2021**, 9, 78 | 7.3 | 14 |
| 354 | Targeting Parthanatos in Ischemic Stroke. *Frontiers in Neurology*, **2021**, 12, 662034 | 4.1 | 3 |
| 353 | Protocol for measurement of calcium dysregulation in human induced pluripotent stem cell-derived dopaminergic neurons. *STAR Protocols*, **2021**, 2, 100405 | 1.4 | 1 |
| 352 | Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118, | 11.5 | 13 |
| 351 | Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa. *ELife*, **2021**, 10, | 8.9 | 6 |

| | | | |
|---|---|---|---|
| 350 | Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in Synuclein-Based Mouse Models of Parkinson's Disease. *Journal of Proteome Research*, **2021**, 20, 3428-3443 | 5.6 | 4 |
| 349 | Nanozyme scavenging ROS for prevention of pathologic synuclein transmission in Parkinson disease. *Nano Today*, **2021**, 36, 101027 | 17.9 | 31 |
| 348 | PARIS farnesylation prevents neurodegeneration in models of Parkinson's disease. *Science Translational Medicine*, **2021**, 13, | 17.5 | 6 |
| 347 | ADP-ribosyltransferases, an update on function and nomenclature. *FEBS Journal*, **2021**, | 5.7 | 30 |
| 346 | USP39 promotes non-homologous end-joining repair by poly(ADP-ribose)-induced liquid demixing. *Nucleic Acids Research*, **2021**, 49, 11083-11102 | 20.1 | 1 |
| 345 | Recent advances in preventing neurodegenerative diseases.. *Faculty Reviews*, **2021**, 10, 81 | 1.2 | 1 |
| 344 | AMPA Receptor Surface Expression Is Regulated by S-Nitrosylation of Thorase and Transnitrosylation of NSF. *Cell Reports*, **2020**, 33, 108329 | 10.6 | 4 |
| 343 | Development of a novel method for the quantification of tyrosine 39 phosphorylated and synuclein in human cerebrospinal fluid. *Clinical Proteomics*, **2020**, 17, 13 | 5 | 2 |
| 342 | Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases. *International Review of Cell and Molecular Biology*, **2020**, 353, 1-29 | 6 | 26 |
| 341 | PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency. *Molecular Neurodegeneration*, **2020**, 15, 17 | 19 | 31 |
| 340 | PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson's disease. *Molecular Neurodegeneration*, **2020**, 15, 20 | 19 | 111 |
| 339 | Integration of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons into Rat Brain Circuits. *Bio-protocol*, **2020**, 10, e3746 | 0.9 | |
| 338 | Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis. *Cell Stem Cell*, **2020**, 27, 633-645.e7 | 18 | 13 |
| 337 | Meta-Analysis of the Alzheimer's Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. *Cell Reports*, **2020**, 32, 107908 | 10.6 | 68 |
| 336 | Determinants of seeding and spreading of synuclein pathology in the brain. *Science Advances*, **2020**, 6, | 14.3 | 25 |
| 335 | Microglia and astrocyte dysfunction in parkinson's disease. *Neurobiology of Disease*, **2020**, 144, 105028 | 7.5 | 59 |
| 334 | Molecular Mediation of Prion-like Synuclein Fibrillation from Toxic PFFs to Nontoxic Species.. *ACS Applied Bio Materials*, **2020**, 3, 6096-6102 | 4.1 | 1 |
| 333 | Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons. *Stem Cell Reports*, **2020**, 15, 629-645 | 8 | 21 |

| | | | |
|---|---|---|---|
| 332 | Quantitative mass spectrometric analysis of the mouse cerebral cortex after ischemic stroke. *PLoS ONE*, **2020**, 15, e0231978 | 3.7 | 4 |
| 331 | Transneuronal Propagation of Pathologic Synuclein from the Gut to the Brain Models Parkinson's Disease. *Neuron*, **2019**, 103, 627-641.e7 | 13.9 | 453 |
| 330 | Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson's disease. *Brain*, **2019**, 142, 2380-2401 | 11.2 | 21 |
| 329 | The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration. *Movement Disorders*, **2019**, 34, 959-969 | 7 | 37 |
| 328 | Fyn kinase regulates misfolded synuclein uptake and NLRP3 inflammasome activation in microglia. *Journal of Experimental Medicine*, **2019**, 216, 1411-1430 | 16.6 | 85 |
| 327 | Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis. *Acta Neuropathologica Communications*, **2019**, 7, 125 | 7.3 | 24 |
| 326 | Neurons Derived from Human Induced Pluripotent Stem Cells Integrate into Rat Brain Circuits and Maintain Both Excitatory and Inhibitory Synaptic Activities. *ENeuro*, **2019**, 6, | 3.9 | 9 |
| 325 | Promising disease-modifying therapies for Parkinson's disease. *Science Translational Medicine*, **2019** , 11, | 17.5 | 22 |
| 324 | Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons. *Stem Cells Translational Medicine*, **2019**, 8, 112-123 | 6.9 | 28 |
| 323 | The AAA + ATPase Thorase is neuroprotective against ischemic injury. *Journal of Cerebral Blood Flow and Metabolism*, **2019**, 39, 1836-1848 | 7.3 | 5 |
| 322 | Nitric Oxide Signaling in Neurodegeneration and Cell Death. *Advances in Pharmacology*, **2018**, 82, 57-83 | 5.7 | 41 |
| 321 | DISC1 regulates lactate metabolism in astrocytes: implications for psychiatric disorders. *Translational Psychiatry*, **2018**, 8, 76 | 8.6 | 26 |
| 320 | A homozygous ATAD1 mutation impairs postsynaptic AMPA receptor trafficking and causes a lethal encephalopathy. *Brain*, **2018**, 141, 651-661 | 11.2 | 26 |
| 319 | Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 1635-1640 | 11.5 | 45 |
| 318 | Pathological Endogenous Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy. *Stem Cell Reports*, **2018**, 10, 356-365 | 8 | 40 |
| 317 | Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death and Differentiation*, **2018**, 25, 486-541 | 12.7 | 2160 |
| 316 | GBA1 deficiency negatively affects physiological synuclein tetramers and related multimers. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 798-803 | 11.5 | 106 |
| 315 | Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. *British Journal of Pharmacology*, **2018**, 175, 192-222 | 8.6 | 120 |

| | | | |
|---|---|---|---|
| 314 | Excitotoxic Programmed Cell Death Involves Caspase-Independent Mechanisms **2018**, 3-17 | | 2 |
| 313 | Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. *Molecular Neurodegeneration*, **2018**, 13, 1 | 19 | 63 |
| 312 | Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. *Molecular Neurodegeneration*, **2018**, 13, 8 | 19 | 58 |
| 311 | Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. *Nature Medicine*, **2018**, 24, 931-938 | 50.5 | 413 |
| 310 | Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases. *Cell Death and Differentiation*, **2018**, 25, 542-572 | 12.7 | 64 |
| 309 | Poly(ADP-ribose) drives pathologic synuclein neurodegeneration in Parkinson's disease. *Science*, **2018**, 362, | 33.3 | 196 |
| 308 | The PINK1 p.I368N Mutation Affects Protein Stability and Kinase Activity with Its Structural Change. *Juntendo Medical Journal*, **2018**, 64, 17-30 | 0.1 | |
| 307 | Reply: ATAD1 encephalopathy and stiff baby syndrome: a recognizable clinical presentation. *Brain*, **2018**, 141, e50 | 11.2 | 1 |
| 306 | Synaptic Plasticity onto Dopamine Neurons Shapes Fear Learning. *Neuron*, **2017**, 93, 425-440 | 13.9 | 31 |
| 305 | Neurotoxic reactive astrocytes are induced by activated microglia. *Nature*, **2017**, 541, 481-487 | 50.4 | 2875 |
| 304 | Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics. *Annual Review of Pharmacology and Toxicology*, **2017**, 57, 437-454 | 17.9 | 88 |
| 303 | PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival. *Cell Reports*, **2017**, 18, 918-932 | 10.6 | 101 |
| 302 | Precision therapy for a new disorder of AMPA receptor recycling due to mutations in. *Neurology: Genetics*, **2017**, 3, e130 | 3.8 | 27 |
| 301 | The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. *Molecular Neurodegeneration*, **2017**, 12, 32 | 19 | 37 |
| 300 | Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes. *Experimental Neurology*, **2017**, 298, 191-201 | 5.7 | 45 |
| 299 | T cells from patients with Parkinson's disease recognize synuclein peptides. *Nature*, **2017**, 546, 656-661 | 50.4 | 379 |
| 298 | Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. *Brain*, **2017**, 140, e33 | 11.2 | 2 |
| 297 | Models of LRRK2-Associated Parkinson's Disease. *Advances in Neurobiology*, **2017**, 14, 163-191 | 2.1 | 36 |

| | | | |
|---|---|---|---|
| 296 | Activation mechanisms of the E3 ubiquitin ligase parkin. *Biochemical Journal*, **2017**, 474, 3075-3086 | 3.8 | 30 |
| 295 | Toward the human cellular microRNAome. *Genome Research*, **2017**, 27, 1769-1781 | 9.7 | 95 |
| 294 | Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel. *Science Translational Medicine*, **2017**, 9, | 17.5 | 12 |
| 293 | Two approaches reveal a new paradigm of 'switchable or genetics-influenced allele-specific DNA methylation' with potential in human disease. *Cell Discovery*, **2017**, 3, 17038 | 22.3 | 18 |
| 292 | Cell Death Mechanisms of Neurodegeneration. *Advances in Neurobiology*, **2017**, 15, 403-425 | 2.1 | 68 |
| 291 | Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. *Brain*, **2017**, 140, 98-117 | 11.2 | 88 |
| 290 | Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis. *Journal of Cerebral Blood Flow and Metabolism*, **2017**, 37, 1982-1993 | 7.3 | 17 |
| 289 | c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential. *Journal of Parkinson's Disease*, **2017**, 7, 589-601 | 5.3 | 41 |
| 288 | Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and Synuclein Pathology. *ENeuro*, **2017**, 4, | 3.9 | 19 |
| 287 | Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity. *Science Translational Medicine*, **2016**, 8, 333ra48 | 17.5 | 52 |
| 286 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222 | 10.2 | 3838 |
| 285 | Intracellular Signaling: Mediators and Protective Responses **2016**, 80-89 | | |
| 284 | Activation of tyrosine kinase c-Abl contributes to synuclein-induced neurodegeneration. *Journal of Clinical Investigation*, **2016**, 126, 2970-88 | 15.9 | 88 |
| 283 | Adult Conditional Knockout of PGC-1Leads to Loss of Dopamine Neurons. *ENeuro*, **2016**, 3, | 3.9 | 61 |
| 282 | High-Content Genome-Wide RNAi Screen Reveals as a Key Mediator of Neuronal Cell Death. *ENeuro* , **2016**, 3, | 3.9 | 10 |
| 281 | LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity. *Journal of Chemical Neuroanatomy*, **2016**, 76, 90-97 | 3.2 | 29 |
| 280 | Pathological synuclein transmission initiated by binding lymphocyte-activation gene 3. *Science*, **2016**, 353, | 33.3 | 364 |
| 279 | A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. *Science*, **2016**, 354, | 33.3 | 165 |

| | | | |
|---|---|---|---|
| 278 | LRRK2 pathobiology in Parkinson's disease - virtual inclusion. *Journal of Neurochemistry*, **2016**, 139 Suppl 1, 75-76 | 6 | 3 |
| 277 | TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF. *Brain*, **2015**, 138, 3610-22 | 11.2 | 69 |
| 276 | Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 11696-701 | 11.5 | 149 |
| 275 | Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. *Cell Death and Differentiation*, **2015**, 22, 58-73 | 12.7 | 643 |
| 274 | (Patho-)physiological relevance of PINK1-dependent ubiquitin phosphorylation. *EMBO Reports*, **2015**, 16, 1114-30 | 6.5 | 102 |
| 273 | Lysosomal Enzyme Glucocerebrosidase Protects against A□-42 Oligomer-Induced Neurotoxicity. *PLoS ONE*, **2015**, 10, e0143854 | 3.7 | 9 |
| 272 | The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. *Scientific Reports*, **2014**, 4, 4874 | 4.9 | 145 |
| 271 | MicroRNA-132 dysregulation in Toxoplasma gondii infection has implications for dopamine signaling pathway. *Neuroscience*, **2014**, 268, 128-38 | 3.9 | 77 |
| 270 | Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease. *Cell*, **2014**, 157, 472-485 | 56.2 | 182 |
| 269 | Parkin and PINK1: much more than mitophagy. *Trends in Neurosciences*, **2014**, 37, 315-24 | 13.3 | 258 |
| 268 | Parkin plays a role in sporadic Parkinson's disease. *Neurodegenerative Diseases*, **2014**, 13, 69-71 | 2.3 | 62 |
| 267 | Early-onset Parkinson's disease due to PINK1 p.Q456X mutation--clinical and functional study. *Parkinsonism and Related Disorders*, **2014**, 20, 1274-8 | 3.6 | 25 |
| 266 | Parkin-independent mitophagy requires Drp1 and maintains the integrity of mammalian heart and brain. *EMBO Journal*, **2014**, 33, 2798-813 | 13 | 284 |
| 265 | Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 10209-14 | 11.5 | 203 |
| 264 | Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinson's-like movement disorder. *Nature Communications*, **2014**, 5, 4930 | 17.4 | 87 |
| 263 | Ganglioside regulation of AMPA receptor trafficking. *Journal of Neuroscience*, **2014**, 34, 13246-58 | 6.6 | 29 |
| 262 | MiR-223 regulates the differentiation of immature neurons. *Molecular and Cellular Therapies*, **2014**, 2, | | 21 |
| 261 | Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. *Neurobiology of Disease*, **2014**, 71, 345-58 | 7.5 | 49 |

| | | | |
|---|---|---|---|
| 260 | Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. *British Journal of Pharmacology*, **2014**, 171, 2000-16 | 8.6 | 298 |
| 259 | Botch is a Eglutamyl cyclotransferase that deglycinates and antagonizes Notch. *Cell Reports*, **2014**, 7, 681-8 | 10.6 | 23 |
| 258 | Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. *Human Molecular Genetics*, **2014**, 23, 2055-77 | 5.6 | 93 |
| 257 | Abberant protein synthesis in G2019S LRRK2 Drosophila Parkinson disease-related phenotypes. *Fly*, **2014**, 8, 165-9 | 1.3 | 14 |
| 256 | Msp1/ATAD1 maintains mitochondrial function by facilitating the degradation of mislocalized tail-anchored proteins. *EMBO Journal*, **2014**, 33, 1548-64 | 13 | 113 |
| 255 | Protein microarray characterization of the S-nitrosoproteome. *Molecular and Cellular Proteomics*, **2014**, 13, 63-72 | 7.6 | 49 |
| 254 | LRRK2 pathobiology in Parkinson's disease. *Journal of Neurochemistry*, **2014**, 131, 554-65 | 6 | 113 |
| 253 | Proneural transcription factor Atoh1 drives highly efficient differentiation of human pluripotent stem cells into dopaminergic neurons. *Stem Cells Translational Medicine*, **2014**, 3, 888-98 | 6.9 | 30 |
| 252 | Motor neuron death in ALS: programmed by astrocytes?. *Neuron*, **2014**, 81, 961-963 | 13.9 | 19 |
| 251 | Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. *Nature Neuroscience*, **2013**, 16, 1392-400 | 25.5 | 142 |
| 250 | Reprogramming cellular events by poly(ADP-ribose)-binding proteins. *Molecular Aspects of Medicine* , **2013**, 34, 1066-87 | 16.7 | 115 |
| 249 | Usp16: key controller of stem cells in Down syndrome. *EMBO Journal*, **2013**, 32, 2788-9 | 13 | 5 |
| 248 | New synaptic and molecular targets for neuroprotection in Parkinson's disease. *Movement Disorders*, **2013**, 28, 51-60 | 7 | 30 |
| 247 | Sulfhydration mediates neuroprotective actions of parkin. *Nature Communications*, **2013**, 4, 1626 | 17.4 | 201 |
| 246 | The interplay of microRNA and neuronal activity in health and disease. *Frontiers in Cellular Neuroscience*, **2013**, 7, 136 | 6.1 | 44 |
| 245 | Identification through high-throughput screening of 4'-methoxyflavone and 3',4'-dimethoxyflavone as novel neuroprotective inhibitors of parthanatos. *British Journal of Pharmacology*, **2013**, 169, 1263-78 | 8.6 | 31 |
| 244 | LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization. *PLoS ONE*, **2013**, 8, e77198 | 3.7 | 51 |
| 243 | Development and characterization of a new Parkinson's disease model resulting from impaired autophagy. *Journal of Neuroscience*, **2012**, 32, 16503-9 | 6.6 | 109 |

| | | | |
|---|---|---|---|
| 242 | LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease. *Biochemical Society Transactions*, **2012**, 40, 1074-9 | 5.1 | 21 |
| 241 | MicroRNA-223 is neuroprotective by targeting glutamate receptors. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 18962-7 | 11.5 | 190 |
| 240 | Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. *Trends in Pharmacological Sciences*, **2012**, 33, 365-73 | 13.2 | 62 |
| 239 | Botch promotes neurogenesis by antagonizing Notch. *Developmental Cell*, **2012**, 22, 707-20 | 10.2 | 37 |
| 238 | Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. *Cell Death and Differentiation*, **2012**, 19, 107-20 | 12.7 | 1843 |
| 237 | Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. *Science Translational Medicine*, **2012**, 4, 141ra90 | 17.5 | 381 |
| 236 | ArfGAP1 is a GTPase activating protein for LRRK2: reciprocal regulation of ArfGAP1 by LRRK2. *Journal of Neuroscience*, **2012**, 32, 3877-86 | 6.6 | 81 |
| 235 | Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity. *Human Molecular Genetics*, **2012**, 21, 163-74 | 5.6 | 26 |
| 234 | Animal models of Parkinson's disease: vertebrate genetics. *Cold Spring Harbor Perspectives in Medicine*, **2012**, 2, | 5.4 | 86 |
| 233 | Neurodegenerative phenotypes in an A53T □synuclein transgenic mouse model are independent of LRRK2. *Human Molecular Genetics*, **2012**, 21, 2420-31 | 5.6 | 69 |
| 232 | Measuring the activity of leucine-rich repeat kinase 2: a kinase involved in Parkinson's disease. *Methods in Molecular Biology*, **2012**, 795, 45-54 | 1.4 | 2 |
| 231 | Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. *ACS Chemical Biology*, **2011**, 6, 1021-8 | 4.9 | 112 |
| 230 | PARIS (ZNF746) repression of PGC-1□contributes to neurodegeneration in Parkinson's disease. *Cell* , **2011**, 144, 689-702 | 56.2 | 667 |
| 229 | The AAA+ ATPase Thorase regulates AMPA receptor-dependent synaptic plasticity and behavior. *Cell*, **2011**, 145, 284-99 | 56.2 | 67 |
| 228 | Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). *Science Signaling*, **2011**, 4, ra20 | 8.8 | 286 |
| 227 | MicroRNAs in Parkinson's disease. *Journal of Chemical Neuroanatomy*, **2011**, 42, 127-30 | 3.2 | 95 |
| 226 | Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. *PLoS ONE*, **2011**, 6, e18568 | 3.7 | 297 |
| 225 | Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. *Nature Medicine*, **2011**, 17, 692-9 | 50.5 | 157 |

| | | | |
|---|---|---|---|
| 224 | Recent advances in the genetics of Parkinson's disease. *Annual Review of Genomics and Human Genetics*, **2011**, 12, 301-25 | 9.7 | 301 |
| 223 | Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 14103-8 | 11.5 | 162 |
| 222 | A lysosomal lair for a pathogenic protein pair. *Science Translational Medicine*, **2011**, 3, 91ps28 | 17.5 | 9 |
| 221 | Enhanced autophagy from chronic toxicity of iron and mutant A53T □synuclein: implications for neuronal cell death in Parkinson disease. *Journal of Biological Chemistry*, **2011**, 286, 33380-9 | 5.4 | 68 |
| 220 | Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. *Human Molecular Genetics*, **2011**, 20, 3933-42 | 5.6 | 107 |
| 219 | Resistance to MPTP-neurotoxicity in □synuclein knockout mice is complemented by human □synuclein and associated with increased □synuclein and Akt activation. *PLoS ONE*, **2011**, 6, e16706 | 3.7 | 50 |
| 218 | Neuronal activity regulates hippocampal miRNA expression. *PLoS ONE*, **2011**, 6, e25068 | 3.7 | 45 |
| 217 | Intracellular Signaling: Mediators and Protective Responses **2011**, 154-161 | | |
| 216 | Contributions of poly(ADP-ribose) polymerase-1 and -2 to nuclear translocation of apoptosis-inducing factor and injury from focal cerebral ischemia. *Journal of Neurochemistry*, **2010**, 113, 1012-22 | 6 | 44 |
| 215 | Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. *Nature Medicine*, **2010**, 16, 998-1000 | 50.5 | 303 |
| 214 | NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. *Journal of Clinical Investigation*, **2010**, 120, 2446-56 | 15.9 | 39 |
| 213 | Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. *Journal of Biological Chemistry*, **2010**, 285, 29569-76 | 5.4 | 42 |
| 212 | Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 16691-6 | 11.5 | 199 |
| 211 | PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 378-83 | 11.5 | 1199 |
| 210 | Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2010**, 299, R215-21 | 3.2 | 15 |
| 209 | GTPase activity plays a key role in the pathobiology of LRRK2. *PLoS Genetics*, **2010**, 6, e1000902 | 6 | 163 |
| 208 | The impact of genetic research on our understanding of Parkinson's disease. *Progress in Brain Research*, **2010**, 183, 21-41 | 2.9 | 26 |
| 207 | Neonatal stroke in mice causes long-term changes in neuronal Notch-2 expression that may contribute to prolonged injury. *Stroke*, **2010**, 41, S64-71 | 6.7 | 20 |

| | | | |
|---|---|---|---|
| 206 | Genetic animal models of Parkinson's disease. *Neuron*, **2010**, 66, 646-61 | 13.9 | 602 |
| 205 | The role of parkin in familial and sporadic Parkinson's disease. *Movement Disorders*, **2010**, 25 Suppl 1, S32-9 | 7 | 253 |
| 204 | Functional identification of neuroprotective molecules. *PLoS ONE*, **2010**, 5, e15008 | 3.7 | 26 |
| 203 | Excitotoxic Programmed Cell Death Involves Caspase-Independent Mechanisms **2010**, 79-88 | | 0 |
| 202 | S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 4900-5 | 11.5 | 123 |
| 201 | CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 2897-902 | 11.5 | 160 |
| 200 | Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. *Journal of Neuroscience*, **2009**, 29, 11257-62 | 6.6 | 165 |
| 199 | Outer mitochondrial membrane localization of apoptosis-inducing factor: mechanistic implications for release. *ASN Neuro*, **2009**, 1, | 5.3 | 59 |
| 198 | Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. *Free Radical Biology and Medicine*, **2009**, 47, 1049-56 | 7.8 | 49 |
| 197 | Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons. *Molecular Neurodegeneration*, **2009**, 4, 34 | 19 | 65 |
| 196 | Understanding microRNAs in neurodegeneration. *Nature Reviews Neuroscience*, **2009**, 10, 837-41 | 13.5 | 226 |
| 195 | Calpain activation is not required for AIF translocation in PARP-1-dependent cell death (parthanatos). *Journal of Neurochemistry*, **2009**, 110, 687-96 | 6 | 77 |
| 194 | Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). *Journal of Neuroscience*, **2009**, 29, 15846-50 | 6.6 | 103 |
| 193 | Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. *Experimental Neurology*, **2009**, 218, 193-202 | 5.7 | 264 |
| 192 | SnapShot: pathogenesis of Parkinson's disease. *Cell*, **2009**, 139, 440.e1-2 | 56.2 | 12 |
| 191 | Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. *Journal of Neuropathology and Experimental Neurology*, **2009**, 68, 994-1005 | 3.1 | 65 |
| 190 | Parthanatos, a messenger of death. *Frontiers in Bioscience - Landmark*, **2009**, 14, 1116-28 | 2.8 | 259 |
| 189 | What causes cell death in Parkinson's disease?. *Annals of Neurology*, **2008**, 64 Suppl 2, S3-15 | 9.4 | 71 |

| | | | |
|---|---|---|---|
| 188 | Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. *Nature Cell Biology*, **2008**, 10, 866-73 | 23.4 | 307 |
| 187 | Parkin mediates the degradation-independent ubiquitination of Hsp70. *Journal of Neurochemistry*, **2008**, 105, 1806-19 | 6 | 81 |
| 186 | Autophagy-mediated clearance of aggresomes is not a universal phenomenon. *Human Molecular Genetics*, **2008**, 17, 2570-82 | 5.6 | 130 |
| 185 | Advances in neuronal cell death 2007. *Stroke*, **2008**, 39, 286-8 | 6.7 | 25 |
| 184 | Lysine 63-linked polyubiquitin potentially partners with p62 to promote the clearance of protein inclusions by autophagy. *Autophagy*, **2008**, 4, 251-253 | 10.2 | 48 |
| 183 | The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. *Journal of Neuroscience*, **2008**, 28, 3384-91 | 6.6 | 158 |
| 182 | Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. *Nucleic Acids Research*, **2008**, 36, 6959-76 | 20.1 | 298 |
| 181 | Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. *Human Molecular Genetics*, **2008**, 17, 431-9 | 5.6 | 330 |
| 180 | Mitochondrial and nuclear cross talk in cell death: parthanatos. *Annals of the New York Academy of Sciences*, **2008**, 1147, 233-41 | 6.5 | 222 |
| 179 | Genetic Models of Familial Parkinson's Disease **2008**, 225-236 | | |
| 178 | Parthanatos **2008**, 143-156 | | 0 |
| 177 | Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. *Journal of Neurochemistry*, **2007**, 100, 368-81 | 6 | 88 |
| 176 | Dynamic and redundant regulation of LRRK2 and LRRK1 expression. *BMC Neuroscience*, **2007**, 8, 102 | 3.2 | 121 |
| 175 | Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. *Brain Research*, **2007**, 1155, 208-19 | 3.7 | 125 |
| 174 | MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. *Neurobiology of Disease*, **2007**, 26, 312-22 | 7.5 | 58 |
| 173 | Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. *Journal of Biological Chemistry*, **2007**, 282, 16441-53 | 5.4 | 202 |
| 172 | DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 14807-12 | 11.5 | 387 |
| 171 | Parkinson Disease: Molecular Insights **2007**, 221-239 | | |

| | | | |
|---|---|---|---|
| 170 | Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. *Journal of Biological Chemistry*, **2007**, 282, 12310-8 | 5.4 | 71 |
| 169 | Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. *Human Molecular Genetics*, **2007**, 16, 223-32 | 5.6 | 466 |
| 168 | Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death. *Neurobiology of Aging*, **2007**, 28, 1709-17 | 5.6 | 47 |
| 167 | Influence of duration of focal cerebral ischemia and neuronal nitric oxide synthase on translocation of apoptosis-inducing factor to the nucleus. *Neuroscience*, **2007**, 144, 56-65 | 3.9 | 37 |
| 166 | Spatial and functional relationship between poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in the brain. *Neuroscience*, **2007**, 148, 198-211 | 3.9 | 32 |
| 165 | Role of nitric oxide in Parkinson's disease **2006**, 109, 33-41 | | 127 |
| 164 | Localization of LRRK2 to membranous and vesicular structures in mammalian brain. *Annals of Neurology*, **2006**, 60, 557-69 | 9.4 | 429 |
| 163 | Neuroprotection by pharmacologic blockade of the GAPDH death cascade. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 3887-9 | 11.5 | 200 |
| 162 | Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 18314-9 | 11.5 | 571 |
| 161 | Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. *Journal of Biological Chemistry*, **2006**, 281, 16193-6 | 5.4 | 84 |
| 160 | Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy. *Journal of Neuroscience*, **2006**, 26, 3685-96 | 6.6 | 72 |
| 159 | Poly(ADP-ribose) (PAR) polymer is a death signal. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 18308-13 | 11.5 | 494 |
| 158 | Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases?. *Neurobiology of Aging*, **2006**, 27, 524-9 | 5.6 | 114 |
| 157 | Diagnosis and treatment of Parkinson disease: molecules to medicine. *Journal of Clinical Investigation*, **2006**, 116, 1744-54 | 15.9 | 461 |
| 156 | Mining for survival genes. *Biochemical Society Transactions*, **2006**, 34, 1307-9 | 5.1 | 4 |
| 155 | Kinase activity of mutant LRRK2 mediates neuronal toxicity. *Nature Neuroscience*, **2006**, 9, 1231-3 | 25.5 | 540 |
| 154 | EndoG is dispensable in embryogenesis and apoptosis. *Cell Death and Differentiation*, **2006**, 13, 1147-55 | 12.7 | 66 |
| 153 | Differential effect of PARP-2 deletion on brain injury after focal and global cerebral ischemia. *Journal of Cerebral Blood Flow and Metabolism*, **2006**, 26, 135-41 | 7.3 | 54 |

| | | | |
|---|---|---|---|
| 152 | Lessons from Drosophila models of DJ-1 deficiency. *Science of Aging Knowledge Environment: SAGE KE*, **2006**, 2006, pe2 | | 26 |
| 151 | Ubiquitination by Parkin Implications in Parkinson Disease **2006**, 213-224 | | |
| 150 | PARP and the Release of Apoptosis-Inducing Factor from Mitochondria **2006**, 103-117 | | 3 |
| 149 | The road to survival goes through PARG. *Cell Cycle*, **2005**, 4, 397-9 | 4.7 | 17 |
| 148 | Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. *Human Molecular Genetics*, **2005**, 14, 3885-97 | 5.6 | 176 |
| 147 | Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. *Human Molecular Genetics*, **2005**, 14, 2063-73 | 5.6 | 348 |
| 146 | Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. *Journal of Neuroscience*, **2005**, 25, 5544-52 | 6.6 | 202 |
| 145 | Molecular pathophysiology of Parkinson's disease. *Annual Review of Neuroscience*, **2005**, 28, 57-87 | 17 | 982 |
| 144 | Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 16842-7 | 11.5 | 933 |
| 143 | Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. *Molecular Brain Research*, **2005**, 134, 103-8 | | 55 |
| 142 | To die or grow: Parkinson's disease and cancer. *Trends in Neurosciences*, **2005**, 28, 348-52 | 13.3 | 91 |
| 141 | Recent advances in our understanding of Parkinson's disease. *Drug Discovery Today Disease Mechanisms*, **2005**, 2, 427-433 | | 12 |
| 140 | Mediation of cell death by poly(ADP-ribose) polymerase-1. *Pharmacological Research*, **2005**, 52, 5-14 | 10.2 | 199 |
| 139 | Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. *Human Molecular Genetics*, **2005**, 14, 3801-11 | 5.6 | 288 |
| 138 | The involvement of nitric oxide in the enhanced expression of mu-opioid receptors during intestinal inflammation in mice. *British Journal of Pharmacology*, **2005**, 145, 758-66 | 8.6 | 28 |
| 137 | The role of nitric oxide and PARP in neuronal cell death **2005**, 146-156 | | |
| 136 | Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. *Human Molecular Genetics*, **2005**, 14, 2571-86 | 5.6 | 183 |
| 135 | Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. *Human Molecular Genetics*, **2005**, 14, 71-84 | 5.6 | 218 |

| | | | |
|---|---|---|---|
| 134 | Comment on "S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function". *Science*, **2005**, 308, 1870; author reply 1870 | 33.3 | 20 |
| 133 | Bcl-x is required for proper development of the mouse substantia nigra. *Journal of Neuroscience*, **2005**, 25, 6721-8 | 6.6 | 103 |
| 132 | S-nitrosylation in Parkinson's disease and related neurodegenerative disorders. *Methods in Enzymology*, **2005**, 396, 139-50 | 1.7 | 33 |
| 131 | Identification and evaluation of NO-regulated genes by differential analysis of primary cDNA library expression (DAzLE). *Methods in Enzymology*, **2005**, 396, 359-68 | 1.7 | 1 |
| 130 | Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. *Proceedings of the National Academy of Sciences of the United States of America*, **2005** , 102, 18676-81 | 11.5 | 359 |
| 129 | Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. *Journal of Neuroscience*, **2005**, 25, 2002-9 | 6.6 | 431 |
| 128 | Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. *Journal of Neuroscience*, **2005**, 25, 7968-78 | 6.6 | 204 |
| 127 | Genetics Of Parkinson Disease. *Neurological Disease and Therapy*, **2005**, 611-631 | | |
| 126 | Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 17699-704 | 11.5 | 260 |
| 125 | Loss of locus coeruleus neurons and reduced startle in parkin null mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 10744-9 | 11.5 | 275 |
| 124 | Identification of calcium- and nitric oxide-regulated genes by differential analysis of library expression (DAzLE). *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 647-52 | 11.5 | 30 |
| 123 | BAD is a pro-survival factor prior to activation of its pro-apoptotic function. *Journal of Biological Chemistry*, **2004**, 279, 42240-9 | 5.4 | 39 |
| 122 | Identification and analysis of plasticity-induced late-response genes. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 2145-50 | 11.5 | 54 |
| 121 | Role of AIF in caspase-dependent and caspase-independent cell death. *Oncogene*, **2004**, 23, 2785-96 | 9.2 | 441 |
| 120 | PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. *Journal of Neurochemistry*, **2004**, 90, 1068-75 | 6 | 233 |
| 119 | Deadly conversations: nuclear-mitochondrial cross-talk. *Journal of Bioenergetics and Biomembranes*, **2004**, 36, 287-94 | 3.7 | 146 |
| 118 | Parkin-associated Parkinson's disease. *Cell and Tissue Research*, **2004**, 318, 175-84 | 4.2 | 116 |
| 117 | Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. *Hepatology*, **2004**, 39, 403-11 | 11.2 | 124 |

| | | | |
|---|---|---|---|
| 116 | S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. *Science*, **2004**, 304, 1328-31 | 33.3 | 656 |
| 115 | Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. *Journal of Neuroscience*, **2004**, 24, 10963-73 | 6.6 | 240 |
| 114 | Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. *Trends in Pharmacological Sciences*, **2004**, 25, 259-64 | 13.2 | 386 |
| 113 | Genomics-Proteomics and Stroke: Introduction. *Stroke*, **2004**, 35, 2731-2734 | 6.7 | 1 |
| 112 | What have genetically engineered mice taught us about ischemic injury?. *Current Molecular Medicine*, **2004**, 4, 207-25 | 2.5 | 14 |
| 111 | Intracellular Signaling: Mediators and Protective Responses **2004**, 895-902 | | |
| 110 | The cast of molecular characters in Parkinson's disease: felons, conspirators, and suspects. *Annals of the New York Academy of Sciences*, **2003**, 991, 80-92 | 6.5 | 32 |
| 109 | Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease. *Annals of the New York Academy of Sciences*, **2003**, 991, 132-9 | 6.5 | 101 |
| 108 | Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. *Journal of Biological Chemistry*, **2003**, 278, 48120-8 | 5.4 | 123 |
| 107 | Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. *Journal of Biological Chemistry*, **2003**, 278, 13047-55 | 5.4 | 68 |
| 106 | Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses. *NeuroMolecular Medicine*, **2003**, 4, 95-108 | 4.6 | 47 |
| 105 | New insights into Parkinson's disease. *Journal of Neurology*, **2003**, 250 Suppl 3, III15-24 | 5.5 | 32 |
| 104 | Involvement of poly ADP ribosyl polymerase-1 in acute but not chronic zinc toxicity. *European Journal of Neuroscience*, **2003**, 18, 1402-9 | 3.5 | 34 |
| 103 | A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. *Journal of Neurochemistry*, **2003**, 87, 1558-67 | 6 | 173 |
| 102 | Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. *Neurobiology of Disease*, **2003**, 14, 303-17 | 7.5 | 165 |
| 101 | Poly (ADP-ribose) polymerase and brain ischemia. *International Congress Series*, **2003**, 1252, 21-29 | | |
| 100 | Molecular pathways of neurodegeneration in Parkinson's disease. *Science*, **2003**, 302, 819-22 | 33.3 | 1382 |
| 99 | 37-kDa laminin receptor precursor modulates cytotoxic necrotizing factor 1-mediated RhoA activation and bacterial uptake. *Journal of Biological Chemistry*, **2003**, 278, 16857-62 | 5.4 | 96 |

| | | | |
|---|---|---|---|
| 98 | Rare genetic mutations shed light on the pathogenesis of Parkinson disease. *Journal of Clinical Investigation*, **2003**, 111, 145-51 | 15.9 | 61 |
| 97 | Rare genetic mutations shed light on the pathogenesis of Parkinson disease. *Journal of Clinical Investigation*, **2003**, 111, 145-151 | 15.9 | 152 |
| 96 | Poly(ADP-ribose) polymerase impairs early and long-term experimental stroke recovery. *Stroke*, **2002**, 33, 1101-6 | 6.7 | 117 |
| 95 | The genetics of Parkinson's disease. *Current Neurology and Neuroscience Reports*, **2002**, 2, 439-46 | 6.6 | 27 |
| 94 | A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism. *Journal of Neurochemistry*, **2002**, 83, 186-92 | 6 | 67 |
| 93 | Neuroprotective and neurorestorative strategies for Parkinson's disease. *Nature Neuroscience*, **2002**, 5 Suppl, 1058-61 | 25.5 | 139 |
| 92 | The orphan nuclear receptor, steroidogenic factor 1, regulates neuronal nitric oxide synthase gene expression in pituitary gonadotropes. *Molecular Endocrinology*, **2002**, 16, 2828-39 | | 24 |
| 91 | Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. *Journal of Cell Biology*, **2002**, 158, 507-17 | 7.3 | 405 |
| 90 | Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. *Science*, **2002**, 297, 259-63 | 33.3 | 1508 |
| 89 | Mechanisms of ischemic tolerance **2002**, 58-71 | | |
| 88 | Neuroprotective effect of sigma(1)-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is linked to reduced neuronal nitric oxide production. *Stroke*, **2001**, 32, 1613-20 | 6.7 | 77 |
| 87 | Reduction of functional N-methyl-D-aspartate receptors in neurons by RNase P-mediated cleavage of the NR1 mRNA. *Journal of Neurochemistry*, **2001**, 76, 1386-94 | 6 | 7 |
| 86 | Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. *European Journal of Neuroscience*, **2001**, 13, 1683-93 | 3.5 | 69 |
| 85 | Neuroimmunophilins: novel neuroprotective and neuroregenerative targets. *Annals of Neurology*, **2001**, 50, 6-16 | 9.4 | 75 |
| 84 | Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. *Nature Medicine*, **2001**, 7, 1144-50 | 50.5 | 643 |
| 83 | Parkin: clinical aspects and neurobiology. *Clinical Neuroscience Research*, **2001**, 1, 467-482 | | 13 |
| 82 | FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 2425-30 | 11.5 | 110 |
| 81 | Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. *Human Molecular Genetics*, **2001**, 10, 919-26 | 5.6 | 387 |

| | | | |
|---|---|---|---|
| 80 | The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. *Trends in Neurosciences*, **2001**, 24, S7-14 | 13.3 | 158 |
| 79 | The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. *Trends in Neurosciences*, **2001**, 24, 7-14 | 13.3 | 151 |
| 78 | Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. *Science*, **2001**, 291, 2423-8 | 33.3 | 944 |
| 77 | Overview of the pathway and functions of nitric oxide. *Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al ]*, **2001**, Chapter 10, Unit 10.1 | 1 | |
| 76 | Histochemical analysis of nitric oxide synthase by NADPH diaphorase staining. *Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al ]*, **2001**, Chapter 10, Unit 10.6 | 1 | 5 |
| 75 | Brain serotonin dysfunction accounts for aggression in male mice lacking neuronal nitric oxide synthase. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 1277-81 | 11.5 | 92 |
| 74 | NMDA but not non-NMDA excitotoxicity is mediated by Poly(ADP-ribose) polymerase. *Journal of Neuroscience*, **2000**, 20, 8005-11 | 6.6 | 194 |
| 73 | Stroke outcome in double-mutant antioxidant transgenic mice. *Stroke*, **2000**, 31, 2685-91 | 6.7 | 42 |
| 72 | Requirement for nitric oxide activation of p21(ras)/extracellular regulated kinase in neuronal ischemic preconditioning. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 436-41 | 11.5 | 298 |
| 71 | Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 13354-9 | 11.5 | 835 |
| 70 | Dynamic regulation of neuronal NO synthase transcription by calcium influx through a CREB family transcription factor-dependent mechanism. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 8617-22 | 11.5 | 149 |
| 69 | Oxidative stress and genetics in the pathogenesis of Parkinson's disease. *Neurobiology of Disease*, **2000**, 7, 240-50 | 7.5 | 371 |
| 68 | Neuronal ischaemic preconditioning. *Trends in Pharmacological Sciences*, **2000**, 21, 423-4 | 13.2 | 51 |
| 67 | Influence of Nitric Oxide on Neuroendocrine Function and Behavior **2000**, 429-438 | | 3 |
| 66 | Neurotoxic Actions and Mechanisms of Nitric Oxide **2000**, 695-710 | | 4 |
| 65 | In vitro and in vivo effects of genistein on murine alveolar macrophage TNF alpha production. *Cellular and Molecular Neurobiology*, **1999**, 23, 231-9 | 4.6 | 205 |
| 64 | Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 5774-9 | 11.5 | 333 |
| 63 | Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. *Nature Medicine*, **1999**, 5, 1403-9 | 50.5 | 906 |

| | | | |
|---|---|---|---|
| 62 | Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. *Nature Genetics*, **1999**, 22, 110-4 | 36.3 | 440 |
| 61 | Role of neuronal and endothelial nitric oxide synthase in nitric oxide generation in the brain following cerebral ischemia. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **1999**, 1455, 23-34 | 6.9 | 113 |
| 60 | Lack of involvement of neuronal nitric oxide synthase in the pathogenesis of a transgenic mouse model of familial amyotrophic lateral sclerosis. *Neuroscience*, **1999**, 90, 1483-92 | 3.9 | 79 |
| 59 | Glutamate-stimulated calcium activation of Ras/Erk pathway mediated by nitric oxide. *Diabetes Research and Clinical Practice*, **1999**, 45, 113-5 | 7.4 | 31 |
| 58 | Nuclear targeting of mutant Huntingtin increases toxicity. *Molecular and Cellular Neurosciences*, **1999**, 14, 121-8 | 4.8 | 166 |
| 57 | Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats. *Stroke*, **1999**, 30, 1279-85 | 6.7 | 54 |
| 56 | Free radicals as mediators of neuronal injury. *Cellular and Molecular Neurobiology*, **1998**, 18, 667-82 | 4.6 | 187 |
| 55 | Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. *Human Molecular Genetics*, **1998**, 7, 783-90 | 5.6 | 269 |
| 54 | mdx muscle pathology is independent of nNOS perturbation. *Human Molecular Genetics*, **1998**, 7, 823-9 | 5.6 | 94 |
| 53 | Nitric oxide in neurodegeneration. *Progress in Brain Research*, **1998**, 118, 215-29 | 2.9 | 296 |
| 52 | Nitric oxide mediates N-methyl-D-aspartate receptor-induced activation of p21ras. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 5773-8 | 11.5 | 183 |
| 51 | Nitric Oxide: Diverse Actions in the Central and Peripheral Nervous Systems. *Neuroscientist*, **1998**, 4, 96-112 | 7.2 | 19 |
| 50 | Impaired Ovulation in Mice with Targeted Deletion of the Neuronal Isoform of Nitric Oxide Synthase. *Molecular Medicine*, **1998**, 4, 658-664 | 6.2 | 20 |
| 49 | Manganese superoxide dismutase protects nNOS neurons from NMDA and nitric oxide-mediated neurotoxicity. *Journal of Neuroscience*, **1998**, 18, 2040-55 | 6.6 | 239 |
| 48 | Neuronal (type I) nitric oxide synthase regulates nuclear factor kappaB activity and immunologic (type II) nitric oxide synthase expression. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 2676-80 | 11.5 | 177 |
| 47 | Differential susceptibility to neurotoxicity mediated by neurotrophins and neuronal nitric oxide synthase. *Journal of Neuroscience*, **1997**, 17, 4633-41 | 6.6 | 95 |
| 46 | Inhibition of Neuronal Nitric Oxide Synthase Increases Aggressive Behavior in Mice. *Molecular Medicine*, **1997**, 3, 610-616 | 6.2 | 84 |
| 45 | Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. *Nature Medicine*, **1997**, 3, 571-4 | 50.5 | 121 |

| | | | |
|---|---|---|---|
| 44 | Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. *Nature Medicine*, **1997**, 3, 1089-95 | 50.5 | 923 |
| 43 | Aggressive behavior in male mice lacking the gene for neuronal nitric oxide synthase requires testosterone. *Brain Research*, **1997**, 769, 66-70 | 3.7 | 58 |
| 42 | Effects of nitric oxide on neuroendocrine function and behavior. *Frontiers in Neuroendocrinology*, **1997**, 18, 463-91 | 8.9 | 90 |
| 41 | Nitric oxide synthase in models of focal ischemia. *Stroke*, **1997**, 28, 1283-8 | 6.7 | 515 |
| 40 | Nitric oxide in neuronal degeneration. *Experimental Biology and Medicine*, **1996**, 211, 33-40 | 3.7 | 107 |
| 39 | Nitric oxide synthase: role as a transmitter/mediator in the brain and endocrine system. *Annual Review of Medicine*, **1996**, 47, 219-27 | 17.4 | 133 |
| 38 | Nitric oxide neurotoxicity. *Journal of Chemical Neuroanatomy*, **1996**, 10, 179-90 | 3.2 | 422 |
| 37 | Nitric oxide actions in neurochemistry. *Neurochemistry International*, **1996**, 29, 97-110 | 4.4 | 157 |
| 36 | Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. *Science*, **1996**, 274, 1917-21 | 33.3 | 369 |
| 35 | Nitric Oxide Synthase Inhibitors. *CNS Drugs*, **1996**, 6, 351-357 | 6.7 | 5 |
| 34 | NADPH Diaphorase Staining. *Methods in Neurosciences*, **1996**, 31, 62-67 | | 2 |
| 33 | Function of Nitric Oxide in Neuronal Cell Death. *Methods in Neurosciences*, **1996**, 228-240 | | 1 |
| 32 | Nitric Oxide Toxicity in Central Nervous System Cultures. *Methods in Neurosciences*, **1996**, 30, 26-43 | | 2 |
| 31 | Generation of isoform-specific antibodies to nitric oxide synthases. *Methods in Enzymology*, **1996**, 268, 349-58 | 1.7 | 2 |
| 30 | Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 5037-42 | 11.5 | 129 |
| 29 | Neurobiology of nitric oxide. *Critical Reviews in Neurobiology*, **1996**, 10, 291-316 | | 228 |
| 28 | Nitric Oxide Actions in the Nervous System **1996**, 247-262 | | |
| 27 | Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. *Nature*, **1995**, 378, 383-6 | 50.4 | 533 |

| | | | |
|---|---|---|---|
| 26 | Nitric oxide: role in neurotoxicity. *Clinical and Experimental Pharmacology and Physiology*, **1995**, 22, 305-8 | 3 | 109 |
| 25 | REVIEW ? : Nitric Oxide: Actions and Pathological Roles. *Neuroscientist*, **1995**, 1, 7-18 | 7.6 | 94 |
| 24 | Physiological and toxicological actions of nitric oxide in the central nervous system. *Advances in Pharmacology*, **1995**, 34, 323-42 | 5.7 | 52 |
| 23 | Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase. *Annals of Neurology*, **1995**, 37, 115-8 | 9.4 | 63 |
| 22 | Nitric Oxide Neurotoxicity in Primary Neuronal Cultures **1995**, 3-15 | | |
| 21 | Molecular mechanisms of nitric oxide actions in the brain. *Annals of the New York Academy of Sciences*, **1994**, 738, 76-85 | 6.5 | 91 |
| 20 | Receptor alterations in subcortical structures after bilateral middle cerebral artery infarction of the cerebral cortex. *Experimental Neurology*, **1994**, 128, 88-96 | 5.7 | 13 |
| 19 | Cyclic nucleotide dependent phosphorylation of neuronal nitric oxide synthase inhibits catalytic activity. *Neuropharmacology*, **1994**, 33, 1245-51 | 5.5 | 126 |
| 18 | Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures. *Neuropharmacology*, **1994**, 33, 1425-30 | 5.5 | 232 |
| 17 | gp120 neurotoxicity in primary cortical cultures. *Advances in Neuroimmunology*, **1994**, 4, 167-73 | | 21 |
| 16 | Alterations in cortical muscarinic receptors following cholinotoxin (AF64A) lesion of the rat nucleus basalis magnocellularis. *Neurobiology of Aging*, **1992**, 13, 25-32 | 5.6 | 21 |
| 15 | A novel neuronal messenger molecule in brain: the free radical, nitric oxide. *Annals of Neurology*, **1992**, 32, 297-311 | 9.4 | 768 |
| 14 | Functional recovery of supersensitive dopamine receptors after intrastriatal grafts of fetal substantia nigra. *Experimental Neurology*, **1991**, 111, 282-92 | 5.7 | 54 |
| 13 | Downregulation of muscarinic receptors in the rat caudate-putamen after lesioning of the ipsilateral nigrostriatal dopamine pathway with 6-hydroxydopamine (6-OHDA): normalization by fetal mesencephalic transplants. *Brain Research*, **1991**, 540, 145-52 | 3.7 | 21 |
| 12 | Reversal of nigrostriatal-lesion-induced receptor alterations by grafting of fetal mesencephalic dopaminergic neurons. *Advances in Experimental Medicine and Biology*, **1991**, 287, 221-35 | 3.6 | |
| 11 | Characterization of polyamines having agonist, antagonist, and inverse agonist effects at the polyamine recognition site of the NMDA receptor. *Neuron*, **1990**, 5, 199-208 | 13.9 | 166 |
| 10 | Hippocampal muscarinic supersensitivity after AF64A medial septal lesion excludes M1 receptors. *Brain Research Bulletin*, **1990**, 25, 311-7 | 3.9 | 16 |
| 9 | Muscarinic and dopaminergic receptor subtypes on striatal cholinergic interneurons. *Brain Research Bulletin*, **1990**, 25, 903-12 | 3.9 | 34 |

| | | | |
|---|---|---|---|
| 8 | Normalization of subtype-specific muscarinic receptor binding in the denervated hippocampus by septodiagonal band grafts. *Experimental Neurology*, **1989**, 106, 115-24 | 5.7 | 61 |
| 7 | Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen. *Life Sciences*, **1988**, 42, 1933-9 | 6.8 | 72 |
| 6 | Parkin and Neurodegeneration211-236 | | |
| 5 | Experience-dependent translational state defined by cell type-specific ribosome profiling | | 1 |
| 4 | Complement and coagulation cascades are potentially involved in dopaminergic neurodegeneration in □synuclein-based mouse models of Parkinson□ disease | | 2 |
| 3 | Host regulator PARP1 contributes to sex differences and immune responses in a mouse model of tuberculosis | | 1 |
| 2 | Aplp1 and the Aplp1-Lag3 Complex facilitates transmission of pathologic □synuclein | | 3 |
| 1 | Parkin and Neurodegeneration211-236 | | |